Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Assets Average (2017 - 2025)

Historic Assets Average for Rhythm Pharmaceuticals (RYTM) over the last 9 years, with Q3 2025 value amounting to $439.8 million.

  • Rhythm Pharmaceuticals' Assets Average rose 1800.18% to $439.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $439.8 million, marking a year-over-year increase of 1800.18%. This contributed to the annual value of $362.5 million for FY2024, which is 136.91% up from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Assets Average stood at $439.8 million for Q3 2025, which was up 1800.18% from $379.7 million recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Assets Average peaked at $439.8 million during Q3 2025, and registered a low of $281.2 million during Q2 2022.
  • Its 5-year average for Assets Average is $352.1 million, with a median of $343.5 million in 2023.
  • In the last 5 years, Rhythm Pharmaceuticals' Assets Average soared by 6215.13% in 2021 and then plummeted by 3060.7% in 2022.
  • Quarter analysis of 5 years shows Rhythm Pharmaceuticals' Assets Average stood at $342.7 million in 2021, then rose by 12.66% to $386.0 million in 2022, then decreased by 11.03% to $343.5 million in 2023, then grew by 10.03% to $377.9 million in 2024, then increased by 16.37% to $439.8 million in 2025.
  • Its last three reported values are $439.8 million in Q3 2025, $379.7 million for Q2 2025, and $389.5 million during Q1 2025.